- Home
- WALD vs IPHA Comparison
WALD vs IPHA Comparison
Compare WALD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WALD | IPHA |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United Kingdom | France |
| Employees | 364 | 174 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.8M | 128.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WALD | IPHA |
|---|---|---|
| Price | $1.06 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.75 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 222.7K | 20.6K |
| Earning Date | 03-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.89 | $181.17 |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $1.18 |
| 52 Week High | $3.22 | $2.63 |
Technical Indicators
Market Signals| Indicator | WALD | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 49.61 |
| Support Level | $0.86 | $1.18 |
| Resistance Level | $2.06 | $1.83 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 50.27 | 72.41 |
Price Performance
Historical ComparisonAbout WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.